Navigation Links
Rigaku Publishes EDXRF Method for Iron in Ore Materials
Date:2/20/2013


http://www.rigakuedxrf.com/edxrf/app-notes.html?id=1286_AppNote

About Rigaku

Since its inception in Japan in 1951, Rigaku has been at the forefront of analytical and industrial instrumentation technology. Rigaku and its subsidiaries form a global group focused on life sciences and general purpose analytical instrumentation. With hundreds of major innovations to its credit, Rigaku and its subsidiary companies are world leaders in the fields of small molecule and protein crystallography, X-ray spectrometry and diffraction, X-ray optics, as well as semiconductor metrology. Rigaku employs over 1,100 people globally and its products are in use in more than 70 countries – supporting research, development, production control and quality assurance activities. Throughout the world, Rigaku continuously promotes partnerships, dialog, and innovation within the global scientific and industrial community.

For further information, contact:     

Scott Fess
Product Manager
Applied Rigaku Technologies, Inc.
tel: +1. 512-225-1796
info (at) RigakuEDXRF (dot) com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10448871.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Rigaku ZSX Primus Application Note: Lubricating Oil Analysis by WDXRF According to ASTM D6443-04
2. Rigaku Publishes New Application Note: Cement Raw Meal Analysis by Pressed Powder Method on the ZSX Primus III+
3. Rigaku Publishes New Method for Sulfur Analysis of Petroleum Products by WDXRF According to ASTM D2622-10
4. Rigaku Publishes New Application for Cement Analysis by the Pressed Powder Method on the ZSX Primus III+ According to ASTM C114-11
5. Rigaku Publishes Application Note for Low Concentration Sulfur in Petroleum-based Fuels by WDXRF According to ASTM D2622-10
6. Rigaku Publishes Application Note for Accurate Quantitative Analysis of Ferrosilicon by the Fusion Method Using ZSX Primus III+
7. Rigaku Application Note: Silicate Rock Analysis by Fusion Method
8. Rigaku Publishes New Application Note for Quantitative Analysis of Stainless Steel
9. Rigaku Publishes method for Determination of Sulfur in Bio-gasoline
10. Rigaku publishes new WDXRF Application: Determination of Metals in Copper Concentrate by Advanced Correction Method for Fused Beads
11. Rigaku Announces Method for Quantitative Elemental Analysis of Low-Alloy Steel with the Rigaku ZSX Primus III+ WDXRF Spectrometer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Mass. (PRWEB) , ... July 06, 2015 , ... ... of simpler and cheaper molecular diagnostic tests are key drivers of the global ... growth of personalized medicine and the introduction of new companion diagnostic tests will ...
(Date:7/6/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... Novella Clinical (Novella), to conduct the phase 3 ... glioblastoma. Novella is a full-service, global clinical research organization ... oncology companies. The ICT-107 phase 3 trial will include ... Europe and Canada , ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander ... and professional service industries alike-- typically known for its consummate professionalism-- embarks each ... good cause and break from their day jobs. , "Our motto has always ...
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces that ... Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ) ... in United States District Court, Central District of ... on behalf of a class consisting of all persons ... 2014 and May 13, 2015 inclusive (the "Class Period").  ...
Breaking Biology Technology:Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4
... is the first complement inhibitor to be tested ... Potentia Pharmaceuticals, a,privately held biotechnology company developing ... announced today that the Company,will be presenting its ... drug,candidate, POT-4, during the Retina Subspecialty Day at ...
... Oral Contraceptive,for the Prevention of Pregnancy, ... (NYSE: BRL ) today announced that ... approved its subsidiary Duramed Pharmaceuticals, Inc.,s New ... mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... Initiates Rosetta Green, a Project Which Will Leverage Rosetta Genomics, Proprietary microRNA Technologies and Strong IP ... Range of Plant-Based Applications, The Company has Recently Secured ... Trenches as Certain Milestones are ... Reached, Rosetta has Already Identified microRNAs Correlated With Algal Oil Content ...
Cached Biology Technology:Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 2FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 4FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 5Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... requires activation of a molecule on the surface of B ... uses in its insidious attack on the immune system, University ... Conference (AIDS 2006). , "The research supports a new role ... between cells, with important implications for future studies and drug ...
... Health today provided the clearest picture yet of the prevalence ... with an increased risk of breast cancer. The genes are ... In addition, the study identified key predictors for assessing which ... , Each year, approximately 200,000 women in the United States ...
... with a rare disease in which patients develop multiple, benign ... found throughout the body, according to a report in the ... results from the loss of a gene called CYLD, causing ... studies indicated a role for CYLD in inflammation, but the ...
Cached Biology News:HIV infection requires an accomplice: B cells with special protein direct HIV to T cells 2New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3Gene first linked to rare disease may trigger skin cancer, other tumors 2Gene first linked to rare disease may trigger skin cancer, other tumors 3
... all the reagents required for a fast ... activity in cell and tissue extracts and ... has been tested on samples prepared from ... spleen, and heart muscle from several species, ...
... CHEMICON's Skeletal Myogenesis Kit provides the ... myoblasts into mature skeletal myotubes. By ... is a valuable tool in studies ... in developing strategies for muscle cell ...
... is an anchorage-independent growth assay in soft ... assay for detecting malignant transformation of cells. ... carcinogens or carcinogen inhibitors) are cultured with ... 21-28 days. Following this incubation period, ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
Biology Products: